Comparative Pharmacology

Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

Peritoneal Dialysis Solution

Category C

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

Peritoneal Dialysis Solution

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.

Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.

Clinical Dosing

Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.

Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.

Direct Interaction

None Documented